As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
This article was originally published in PharmAsia News
Executive Summary
Indian generics manufacturer Ranbaxy Laboratories' tangle with U.S. FDA is persisting and will likely impact U.S. sales in 2009